- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07607379
Robotic Dog Intervention on Emotional Well-Being and Quality of Life (ROBDOG)
Effectiveness and Feasibility of a Robotic Dog Intervention on Emotional Well-Being and Quality of Life in Pediatric Patients With Hematological Malignancies Undergoing HSCT
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) experience substantial psychological burden related to intensive treatment, protective isolation, prolonged hospitalization, and immunosuppression. Anxiety, emotional distress, loneliness, and reduced quality of life are common during the post-transplant inpatient period. However, infection control precautions and isolation procedures may limit access to traditional psychosocial support interventions in HSCT settings.
Technology-assisted interventions, particularly social robots, have emerged as promising approaches for supporting emotional well-being in pediatric healthcare environments. AI-powered robotic companion devices may provide interactive engagement, emotional comfort, and opportunities for play during prolonged hospitalization while remaining compatible with infection control requirements.
This pilot randomized controlled study aims to evaluate the effectiveness, feasibility, and acceptability of an AI-powered robotic dog intervention in improving emotional well-being and quality of life in pediatric patients undergoing HSCT.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Eysan Savaş, PhD
- Telefoonnummer: +90 5068418841
- E-mail: eysansavas@gmail.com
Studie Contact Back-up
- Naam: Remziye Semerci, PhD
- Telefoonnummer: +90 535 0112821
- E-mail: remziyesemerci@gmail.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Pediatric patients aged 8-15 years
- Diagnosed with a hematological malignancy and undergoing hematopoietic stem cell transplantation
- Hospitalized in a protective isolation room during the post-transplant inpatient period
- Expected to remain hospitalized under isolation for approximately 30 days post-transplant
- Able to understand and respond to Turkish-language self-report questionnaires
- Clinically stable and deemed eligible for participation by the treating clinical team
- Able to interact with the robotic dog at a basic functional level
Exclusion Criteria:
- Severe cognitive impairment or neurodevelopmental conditions preventing meaningful interaction or self-report
- Acute neurological conditions, delirium, or severe psychiatric crisis (e.g., acute agitation, suicidal ideation)
- Requirement for intensive care, invasive ventilation, or a clinically unstable condition
- Severe visual, hearing, or motor impairments that prevent interaction with the robotic dog
- Additional infection control restrictions prevent the placement or use of the robotic dog in the isolation room
- Anticipated early discharge, transfer, or inability to complete follow-up assessments
- Severe fear, intolerance, or refusal to interact with robotic or electronic devices
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Standard care & Control Group Care
Participants in the control group will receive standard post-transplant inpatient care routinely provided in the HSCT unit.
Standard care includes protective isolation procedures, restricted visitor access, routine clinical monitoring, and infection control practices during the inpatient transplantation period.
Children are permitted to use personal electronic devices and other approved washable or disinfectable materials available within institutional infection control regulations.
No structured psychosocial or technology-assisted intervention will be provided to the control group during the study period.
|
|
|
Experimenteel: Intervention Group (AIBO Group):
Participants assigned to the intervention group will receive standard post-transplant inpatient care in addition to a technology-assisted psychosocial support intervention during the inpatient isolation period following HSCT.
The intervention will be implemented throughout the hospitalization period, and participants will be encouraged to engage with the device regularly during daily care routines.
Baseline assessments will be performed within the first 24-48 hours after HSCT, and follow-up assessments will be conducted weekly for four weeks.
Intervention adherence, feasibility indicators, and adverse events will be monitored throughout the study period.
Infection control procedures will be applied according to institutional protocols.
|
AIBO is an AI-powered interactive robot dog that engages children through play and touch-based interactions, including responding to petting, interacting with a ball, and making simple gestures.
Using visual, auditory, and tactile sensing, AIBO enables spontaneous, child-centered interactions, expressing emotions through eye color changes, tail movements, and vocalizations, while gradually developing more adaptive behaviors through repeated interactions (weight: ~2.2 kg; dimensions: 180 × 293 × 305 mm)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Positive and Negative Affect
Tijdsspanne: Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
Emotional affect will be assessed using the Positive and Negative Affect Schedule for Children (PANAS-C).
The scale evaluates positive and negative emotional states experienced by pediatric patients undergoing hematopoietic stem cell transplantation during the inpatient isolation period.
|
Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
|
Change in Emotional Well-being
Tijdsspanne: Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
Children's emotional well-being will be assessed using the Stirling Children's Well-being Scale.
The scale evaluates positive emotional functioning, interpersonal relationships, and overall psychological well-being in children undergoing hematopoietic stem cell transplantation during the inpatient isolation period.
|
Baseline (Day 1, before intervention initiation) and weekly assessments during the intervention period at Weeks 2, 3, and 4.
|
|
Change in Health-Related Quality of Life
Tijdsspanne: Baseline (Day 1, prior to intervention initiation) and Week 4 (post-intervention assessment after completion of the 4-week intervention period).
|
Health-related quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL 4.0).
The scale consists of 23 items evaluating physical, emotional, social, and school functioning in children and adolescents.
Items are rated on a 5-point Likert scale, with higher scores indicating better health-related quality of life.
|
Baseline (Day 1, prior to intervention initiation) and Week 4 (post-intervention assessment after completion of the 4-week intervention period).
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- KOCUNIVR
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .